Currently Viewing:
American Heart Association Scientific Sessions 2019
Kiersten Combs Discusses Findings of the DAPA-HF Study in Population Without Diabetes
November 17, 2019
Dr Jay Edelberg Outlines the Clinical Burdens and Treatment Options for Hypertrophic Cardiomyopathy
November 17, 2019
Details of DAPA-HF Results Point to Dapagliflozin for Some Heart Failure Patients Without Diabetes
November 17, 2019
In Stable Heart Disease, Study Finds Stents Might Be No Better Than Drugs
November 17, 2019
Dapagliflozin Meets Quality-of-Life Marks, Efficacy Among Seniors, Data Show
November 17, 2019
From Self-Reporting Accuracy to Therapy Access: AHA Posters Cover Issues in Disparities
November 18, 2019
Dr John Pfeifer Outlines Necessary Steps for Preventive Action in Patients With Atrial Fibrillation
November 18, 2019
Sara Levintow Analyzes 2013 ACC/AHA Cholesterol Guidelines in Relation to Trends in US Lipid Testing
November 18, 2019
Plaques May Be Key to Vascepa's Role in Preventing CV Events
November 18, 2019
48-Week Results for Mavacamten Draw Crowd at AHA Session
November 19, 2019
Dr Vinay Kini Discusses the Growing Influence of the EHR in the Transition to Value-Based Care
November 19, 2019
Dr Stephen Heitner Details the Significance of the PIONEER-OLE Study in Treating Obstructive HCM
November 19, 2019
Dr Stephen Heitner Outlines the Next Steps After MAVERICK-HCM Study Findings
November 21, 2019
Dr Stephen Voyce Details Innovations and Preventive Strategies in Detection of Atrial Fibrillation
November 24, 2019
Dr Brent Williams Discusses Study Findings on Detection of Atrial Fibrillation
November 27, 2019
Dr Brandon Fornwalt Discusses the Preventive Efficacy of AI in Monitoring for Atrial Fibrillation
November 30, 2019
Dr Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD
December 04, 2019
Dr Brian Ghoshhajra Details the Significance of the PDS-2 System in Affecting Progression of HoFH
December 05, 2019
Dr Roland Chen Outlines the GUARD-AF Trial as a Preventive Mechanism in Reducing Risk of Stroke
December 06, 2019
Dr Darryl Sleep: Identifying and Treating Elevated LDL-C in Patients Can Mitigate Heart Attack Risk
December 06, 2019
Currently Reading
Dr C. Noel Bairey Merz Discusses ESCaPE-CMD Phase 2 Study Results of Patients With CMD
January 03, 2020
Dr Jay Edelberg Discusses PIONEER-OLE and Design of EXPLORER-HCM in Patients With Obstructive HCM
January 16, 2020
Dr Jay Edelberg Explains Preventive Efficacy and Potential FDA Approval of Mavacamten
January 26, 2020
Dr Roland Chen Discusses the Primary Endpoints of the GUARD-AF Trial for Atrial Fibrillation
January 31, 2020

Dr C. Noel Bairey Merz Discusses ESCaPE-CMD Phase 2 Study Results of Patients With CMD

The phase 2 ESCaPE-CMD study results exhibited a significant improvement in coronary flow reserve for patients with CMD, said C. Noel Bairey Merz, MD, FACC, FAHA, director of the Barbra Streisand Women's Heart Center.


The phase 2 ESCaPE-CMD study results exhibited a significant improvement in coronary flow reserve for patients with CMD, said C. Noel Bairey Merz, MD, FACC, FAHA, director of the Barbra Streisand Women's Heart Center.

Transcript

Can you describe the primary endpoint of the ESCaPE-CMD trial and how positive results were obtained through the CLBS16 treatment?

The trial name is actually ESCaPE-CMD coronary microvascular dysfunction. The primary outcome was invasively measured intracoronary adenosine coronary flow reserve, a rigorous method which we have demonstrated previously as quite reproducible without change in other placebo control trials. What the outcome demonstrated in this trial was an amine score for the group of 20 subjects of 2.0. So, very abnormal coronary flow reserve in these microvascular angina patients improved to a mean of 2.6, a very significant improvement and much better than what we have achieved with other placebo-controlled trials such as ACE inhibitors or high intensity statins.

What impact has CD34 cell therapy had on microvascular function for patients with CMD?

We found in this phase 1, 2 pilot trial of 20 subjects, open label, that the CD34 cells had a quite dramatic effect on invasively measured coronary flow reserve. The average was 2–went up to 2.6, meaning the average patient normalized, and that this was permanent or persistent through a 6-month follow up. A number of patients became angina free.

What do the study results presented at AHA 2019 reveal about the impact of CLBS16 on CMD?

Based on the clinical coronary flow reserve data, these suggest that this will be an effective therapy for coronary microvascular dysfunction patients. Needless to say, this was open label, so we cannot discount a placebo effect–perhaps in the Seattle Angina Questionnaire scores; but the rigor of an objectively measured coronary flow reserve, which we’ve demonstrated previously changes very little with a placebo in other trials that we’ve done, suggest that this may be a beneficial therapy which requires further definitive testing.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up